Human Mu Opioid Receptor ( OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Evidence points to the endogenous opioid system, and the mu-opioid receptor (MOR) in particular, in mediating the rewarding effects of drugs of abuse, including nicotine. A single nucleotide polymorphism (SNP) in the human MOR gene ( OPRM1 A118G) has been shown to alter receptor protein level in preclinical models and smoking behavior in humans. To clarify the underlying mechanisms for these associations, we conducted an in vivo investigation of the effects of OPRM1 A118G genotype on MOR binding potential (BP ND or receptor availability). Twenty-two smokers prescreened for genotype (12 A/A, 10 */G) completed two [ 11 C]carfentanil positron emission tomography (PET) imaging sessions following overnight abstinence and exposure to a nicotine-containing cigarette and a denicotinized cigarette. Independent of session, smokers homozygous for the wild-type OPRM1 A allele exhibited significantly higher levels of MOR BP ND than smokers carrying the G allele in bilateral amygdala, left thalamus, and left anterior cingulate cortex. Among G allele carriers, the extent of subjective reward difference (denicotinized versus nicotine cigarette) was associated significantly with MOR BP ND difference in right amygdala, caudate, anterior cingulate cortex, and thalamus. Future translational investigations can elucidate the role of MORs in nicotine addiction, which may lead to development of novel therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630 · cited 1×
“Left and right hemisphere maskswere defined for the ACC, AMY, CAU, VST, and THA using the Harvard– Oxford probabilistic map (maximal probability threshold: 25%) distributed with FSL software (50).”
MethodA Note on Robust Variance Estimation for Cluster‐Correlated Data
Williams, R. L. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00645.x · Cited by 2,501 · cited 2×
“Because the outcome of interest (MOR BPND by ROI) is continuous, and observations sometimes included repeated measures (across sessions), we analyzed the data using a multiple linear regression and used the cluster-corrected robust covariance matrix to correct SEs (52).”
MethodInfluentialIs there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 2×
“Nicotine upregulates MOR mRNA and protein expression in brain regions important in drug reward in rodents (4, 6) and stimulates endogenous opioid release (7, 8), resulting in MOR activation and dopamine release (9).”
BackgroundPlacebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors
Zubieta, J.-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., Nichols, T. E., & Stohler, C. S. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0439-05.2005 · Cited by 779 · cited 1×
“The dose of [(11)C]carfentanil administered was based on published PET studies (36, 47, 48).”
MethodSelf-citationBrain mechanisms of pain affect and pain modulation
Rainville, P. (2002) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(02)00313-6 · Cited by 634
Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563
Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320
Self-citationWay, B. M., Taylor, S. E., & Eisenberger, N. I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812612106 · Cited by 264
Nicotine Induces Glutamate Release from Thalamocortical Terminals in Prefrontal Cortex
Lambe, E. K., Picciotto, M. R., & Aghajanian, G. K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300032 · Cited by 261 · cited 1×
“MORs located in the thalamus (28) and amygdala (9) decrease excitatory glutamate inputs to the striatum, which influence striatal dopaminergic firing and subsequently nicotine reward.”
BackgroundWICKENS, J. R., BUDD, C. S., HYLAND, B. I., & ARBUTHNOTT, G. W. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1390.016 · Cited by 165
Cited by
Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Callaghan, J. T., Samer, C. F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2149 · Cited by 434
Zhou, H., Rentsch, C. T., Cheng, Z., Kember, R. L., Nunez, Y. Z., Sherva, R. M., Tate, J. P., Dao, C., Xu, K., Polimanti, R., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1206 · Cited by 186
Slavich, G. M., Tartter, M. A., Brennan, P. A., & Hammen, C. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.07.009 · Cited by 83
“Specifically, an A/G transition (A118G) within OPRM1 leads to an amino acid change (N40D) that governs central OPRM1 expression (Mague et al., 2009; Ray et al., 2011), leading to differences in sensitivity to both physical pain and social rejection.”
Genetic Variants and Early Cigarette Smoking and Nicotine Dependence Phenotypes in Adolescents
O'Loughlin, J., Sylvestre, M.-P., Labbe, A., Low, N. C., Roy-Gagnon, M.-H., Dugas, E. N., Karp, I., & Engert, J. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115716 · Cited by 21
“OPRM1 (opioid receptor, mu 1) variants have been associated with increased mu-receptor binding in smokers [72] as well as with smoking reward [73].”
Background
Metadata
- Authors
- Ray, R., Ruparel, K., Newberg, A., Wileyto, E. P., Loughead, J. W., Divgi, C., Blendy, J. A., Logan, J., Zubieta, J.-K., & Lerman, C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-05-16
- Volume
- 108
- Issue
- 22
- Pages
- 9268-9273
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2121923873
- Cited by
- 137
- References
- 12
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Mu Opioid Receptor ( OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. https://app.cochat.ai/papers/10.1073/pnas.1018699108
- The paper
- Ray, R., Ruparel, K., Newberg, A., Wileyto, E. P., Loughead, J. W., Divgi, C., Blendy, J. A., Logan, J., Zubieta, J.-K., & Lerman, C. (2011). Human Mu Opioid Receptor ( OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1018699108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.